{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:47:57Z","timestamp":1791895677868,"version":"4.3.4"},"reference-count":13,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2024,4,1]]},"abstract":"Importance<\/jats:title>The use of patient-reported outcome measures (PROMs) potentially holds promise as an opportunity to improve outcomes and quality of care for patients with skin disease, but the routine use of PROMs remains limited. While the Patient-Reported Outcomes Measurement Information System (PROMIS) has several strengths and domains relevant to those with chronic skin disease, it is not clear which are most useful.<\/jats:p><\/jats:sec>Objective<\/jats:title>To determine which PROMIS domains are most meaningful to those with chronic skin disease to develop a PROMIS profile that effectively captures the experience of living with these skin diseases.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study was based on data gathered from an internet survey that was administered to a sample of adult respondents in the US on the Prolific Platform and ResearchMatch and through the National Psoriasis Foundation. A list of PROMIS domains relevant to chronic skin disease was developed through literature review. These domains were included in a best-worst scaling exercise, in which participants were shown 12 sets of 4 domains and asked to choose which domain in each set was the most important and least important to their experience. Participants completed the survey between December 2022 and June 2023. Data were analyzed in June 2023.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Ratio-scaled preference score for each of the domains.<\/jats:p><\/jats:sec>Results<\/jats:title>Of 939 total participants, 559 (59.5%) were female, 20 (2.1%) gender nonconforming, 7 (0.7%) transgender men, and 1 (0.1%) transgender women; there were 4 American Indian\/Alaska Native (0.4%), 50 Asian (5.3%), 63 Black (6.7%), 66 Hispanic or Latino\/a\/x (7.0%), 2 Native Hawaiian\/Pacific Islander (0.2%), 749 White (79.8%), and 42 multiracial individuals (4.5%). The survey was completed by 200 participants with acne, 316 with psoriasis, 199 with atopic dermatitis, and 224 with various chronic skin diseases. For those with acne, the highest-scored domains were body image (15.66), appearance (14.96), life satisfaction (11.29), depression (9.25), and anxiety (9.18). For those with psoriasis, the highest-scored domains were life satisfaction (11.31), appearance (11.05), itch (10.98), pain (9.97), and body image (8.75). For those with atopic dermatitis, the highest-scored domains were itch (12.60), life satisfaction (11.65), appearance (11.40), body image (11.25), and pain (10.03).<\/jats:p><\/jats:sec>Conclusion and Relevance<\/jats:title>The results of this study suggest that body image, appearance, life satisfaction, itch, pain, anxiety, and depression were highly rated across the surveys. By identifying the PROMIS domains most important to individuals with chronic skin disease, clinicians can choose the domains that are most relevant to patients. In addition, this may guide the construction of a PROMIS profile that effectively captures the experience of living with these skin diseases and can serve as a patient-reported measure of disease severity and treatment effectiveness.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2023.6245","type":"journal-article","created":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T16:01:36Z","timestamp":1708531296000},"page":"441","source":"Crossref","is-referenced-by-count":14,"title":["Identifying Core Outcome Domains in Chronic Skin Disease Using the Best-Worst Scaling Method"],"prefix":"10.1001","volume":"160","author":[{"given":"Ali","family":"Shields","sequence":"first","affiliation":[{"name":"Drexel University College of Medicine, Philadelphia, Pennsylvania"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frances K.","family":"Barg","sequence":"additional","affiliation":[{"name":"Family Medicine and Community Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy Smith","family":"Begolka","sequence":"additional","affiliation":[{"name":"National Eczema Association, Novato, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Sage","sequence":"additional","affiliation":[{"name":"National Eczema Association, Novato, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Druby","sequence":"additional","affiliation":[{"name":"Penn State Health Hampden Medical Center, Enola, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George C.","family":"Gondo","sequence":"additional","affiliation":[{"name":"National Psoriasis Foundation, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Pusic","sequence":"additional","affiliation":[{"name":"Department of Plastic Surgery, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Barbieri","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts"},{"name":"Associate Editor, JAMA Dermatology"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"6","key":"dbr230026r1","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1016\/j.jid.2022.01.008","article-title":"Incorporating patient-reported outcomes as a vital sign for dermatologic clinical care and clinical investigations.","volume":"142","author":"Secrest","year":"2022","journal-title":"J Invest Dermatol"},{"issue":"10","key":"dbr230026r2","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamadermatol.2021.3341","article-title":"Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis.","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"key":"dbr230026r3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1186\/1472-6963-13-211","article-title":"A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting.","volume":"13","author":"Chen","year":"2013","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"dbr230026r4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.2015.63.0830","article-title":"Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial.","volume":"34","author":"Basch","year":"2016","journal-title":"J Clin Oncol"},{"issue":"10","key":"dbr230026r5","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1001\/jamadermatol.2020.2330","article-title":"Quality of life assessed using Skindex-16 scores among patients with acne receiving isotretinoin treatment.","volume":"156","author":"Secrest","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"dbr230026r7","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1016\/j.jid.2019.12.017","article-title":"The value of item banks, CAT, and PROMIS for dermatology.","volume":"140","author":"Terwee","year":"2020","journal-title":"J Invest Dermatol"},{"issue":"9","key":"dbr230026r9","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1001\/jamadermatol.2022.2293","article-title":"Analysis of content and phrasing of health-related quality-of-life patient-reported outcome measures used in patients with acne.","volume":"158","author":"Yoon","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"12","key":"dbr230026r10","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1001\/jamadermatol.2022.3911","article-title":"Use of patient-reported outcomes in acne vulgaris and rosacea clinical trials from 2011 to 2021: a systematic review.","volume":"158","author":"Ly","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"8","key":"dbr230026r11","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1001\/jamadermatol.2022.2260","article-title":"Patient-reported outcome measures for health-related quality of life in patients with acne vulgaris: a systematic review of measure development and measurement properties.","volume":"158","author":"Hopkins","year":"2022","journal-title":"JAMA Dermatol"},{"issue":"4","key":"dbr230026r12","doi-asserted-by":"publisher","DOI":"10.1002\/ski2.v2.4","article-title":"Patient reported outcome measures (PROMS) for body image in dermatology: a systematic review.","volume":"2","author":"Kristensen","year":"2022","journal-title":"Skin Health Dis"},{"issue":"1","key":"dbr230026r13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1001\/archderm.141.1.19","article-title":"Members of the national psoriasis foundation: more extensive disease and better informed about treatment options.","volume":"141","author":"Nijsten","year":"2005","journal-title":"Arch Dermatol"},{"key":"dbr230026r6","unstructured":"Health Catalyst. Survey: fewer than 2 in 10 hospitals regularly use patient-reported outcomes despite Medicare\u2019s impending plans for the measures. Accessed June 1, 2023. https:\/\/www.prnewswire.com\/news-releases\/survey-fewer-than-2-in-10-hospitals-regularly-use-patient-reported-outcomes-despite-medicares-impending-plans-for-the-measures-300306532.html"},{"key":"dbr230026r8","unstructured":"HealthMeasures. PROMIS measures in Epic. Accessed January 18, 2024. https:\/\/www.healthmeasures.net\/implement-healthmeasures\/administration-platforms\/epic"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2815172\/jamadermatology_shields_2024_br_230026_1713299777.90833.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,17]],"date-time":"2024-04-17T15:12:11Z","timestamp":1713366731000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2815172"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,1]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2023.6245","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,1]]}}}